Rosalind Advisors’s Viridian Therapeutics VRDN Stock Holding History

Rosalind Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.9M	Sell	250,401 -199,599	-44%	-$5.93M	1.97%	18
2025 Q4	$14M	Sell	450,000 -150,000	-25%	-$4.11M	4.92%	5
2025 Q3	$12.9M	Sell	600,000 -100,000	-14%	-$1.8M	4.43%	9
2025 Q2	$9.79M	Buy	700,000 +105,000	+18%	+$1.43M	4.64%	7
2025 Q1	$8.02M	Buy	+595,000	New	+$10.1M	3.9%	11
2024 Q3	–	Sell	-300,000	Closed	-$3.9M	–	41
2024 Q2	$3.9M	Hold	300,000	–	–	3%	16
2024 Q1	$5.25M	Sell	300,000 -60,332	-17%	-$1.17M	4.91%	9
2023 Q4	$7.85M	Buy	+360,332	New	+$5.69M	6.46%	5

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rosalind Advisors's VRDN Position: Q1 2026 in Review

Rosalind Advisors reduced its Viridian Therapeutics (VRDN) stake by 44% in Q1 2026, selling an estimated $5.93M and leaving 250,401 shares worth $4.9M. The position accounts for 1.97% of the portfolio, ranked #18.

Rosalind Advisors first reported a position in VRDN in Q4 2023 and has held it in 8 quarters since. The position peaked at $14M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Rosalind Advisors held 250,401 shares of Viridian Therapeutics worth $4.9M as of Q1 2026.
Rosalind Advisors sold 199,599 Viridian Therapeutics shares in Q1 2026, an estimated $5.93M.
Viridian Therapeutics made up 1.97% of Rosalind Advisors's portfolio in Q1 2026, its #18 holding.
Rosalind Advisors first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 8 quarters since.
Rosalind Advisors's Viridian Therapeutics position peaked at $14M in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.